Bristol Myers Lifts 2026 Outlook on Strong Eliquis, New Drug Sales
The drugmaker raised its full-year revenue and profit forecasts after Q2 results exceeded Wall Street estimates. Bristol Myers Squibb increased its 2026 revenue and earnings guidance after second-quarter results surpassed expectations. Revenue rose 6% year-over-year to $12